Tubulin Polymerizing Agent

Epothilone shows activity in metastatic breast cancer, lung cancer

Published in Women's Health Weekly, June 26th, 2003

BMS-247550, an investigational tubulin polymerizing agent under development by Bristol-Myers Squibb Company (BMY), demonstrated activity in metastatic breast cancer and non-small cell lung cancer (NSCLC) according to findings of three phase II studies presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

BMS-247550 is a semi-synthetic analog of epothilone B that induces microtubule stabilization, and has demonstrated activity against taxane sensitive, refractory, and insensitive tumors.

"The activity seen in the epothilone phase II studies is encouraging and we plan to now move forward with the development of this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry